



Pharmacy Services

San Francisco Health Plan Pharmacy & Therapeutics Committee

Wednesday, April 17, 2019

7:30AM – 9:30AM

50 Beale St., 13th Floor, San Francisco, CA 94119

Meeting called by:	James Glauber, MD	Minutes: Sheila Zeno, CPhT (SFHP Pharmacy Analyst) Back-up: Rudy Wu, CPhT (SFHP Pharmacy Analyst)
Meeting Objective:	Vote on proposed formulary and prior authorization(PA) criteria changes	Type of meeting: Quarterly
Attendees:	<p>Voting Members:</p> <p>James Glauber, MD (SFHP Chief Medical Officer) Lisa Ghotbi, Pharm. D (SFHP Director of Pharmacy) Nicholas Jew, MD Joseph Pace, MD Ronald Ruggiero, Pharm. D Jamie Ruiz, MD Ted Li, MD Maria Lopez, Pharm. D Linda Truong, Pharm. D Robert (Brad) Williams, MD Steven Wozniak, MD</p>	<p>Others in Attendance:</p> <p>Kaitlin Hawkins, Pharm. D (SFHP Pharmacist) Ralph Crowder, R.Ph (SFHP Pharmacist) Jessica Shost, Pharm. D (SFHP Pharmacist) Kent Truong, Pharm. D (SFHP Resident Pharmacist) Jenna Heath, Pharm. D (PerformRx Pharmacist) Patrick DeHoratius, Pharm. D (PerformRx Pharmacist)</p> <p>Guests:</p> <p>Mike Pratscher- Osiris Scott Stepien- Osiris Brittany Speer- Lilly Chris Tanaka- Dexcom</p>
Members Absent:	Shawn Houghtaling, Pharm. D	
Meeting Materials:	<p>Summary of all approved changes are posted under “Materials” section at https://www.sfhp.org/files/meeting_agendas/PnT_Committee/PnTMaterialsJanuary2019.pdf</p> <p>SFHP formulary is located at https://www.sfhp.org/providers/pharmacy-services/sfhp-formulary/</p> <p>SFHP prior authorization criteria are located at https://www.sfhp.org/files/providers/formulary/SFHP_Prior_Auth_Criteria.pdf</p>	

	Topic	Brought By	Discussion	Action
1.	Call to Order	James Glauber, MD	<p>The meeting was called to order at 7:33 am.</p> <ul style="list-style-type: none"> • Conflict of interest check • Agenda overview 	<p>Conflict of Interest checked and instructions given. Introduction agenda topics done.</p>
2.	Informational Updates	Lisa Ghotbi, Pharm. D	<p>Topics:</p> <ul style="list-style-type: none"> • April 2019 Pharmacy Director's report <ul style="list-style-type: none"> ○ 2019 Brand Price Increases <ul style="list-style-type: none"> ▪ PBM - PerformRx Re-contracting and Re-Implementation ▪ 24/7/365 phone support for member with pharmacy benefit inquiries ○ First Annual DUR (Drug Utilization Review) Report 	<p>A handout of the director's report was given to the committee members at the meeting.</p>

	Topic	Brought By	Discussion	Action
			<p>to DHCS</p> <ul style="list-style-type: none"> ▪ A 40 page report with five evidence attachments submitted to DHCS on March 21 and accepted with this response by DHCS staff: <i>"We were blown away by the scope and depth of your DUR report and attachments, and the excellent program you have at SFHP."</i> ○ Executive Order N-01-19 <ul style="list-style-type: none"> ▪ Within the executive order, the governor has ordered the carve-out of the pharmacy benefit for Medicaid and to lay a formation for single-payer by 2021. He wants to use the buying power of California to deal with the trends of increasing prices for drugs especially Specialty drugs. ▪ SFHP representatives are participating in meetings with DHCS and legislators. ▪ SFHP supports the EO financial goals but: <ul style="list-style-type: none"> • concern for real-time access and benefit management by plans • concern for the loss of Knox-Keene member protections • concern for a clinically sound formulary and medication accessibility 	
3.	<p>Annual Formulary Review <i>(A summary handout was given to the committee members at the meeting)</i></p>	Lisa Ghotbi, Pharm. D	The committee approved the Annual Review as presented.	<p>VOTE: <u>Review and Approval of 2018 Annual Formulary Review</u> Approved recommendations as presented. <u>Motion:</u> Robert (Brad) Williams, MD <u>2nd:</u> Ronald Ruggiero, Pharm. D <u>Vote:</u> <i>Unanimous approval (8/8)</i> <i>(Other members arrived afterwards)</i></p>
4.	<p>Review and Approval of January 16, 2019 P&T minutes <i>(pp.5 - 13 of April 2019 P&T Packet)</i></p>	James Glauber, MD	The committee approved the minutes as presented.	<p>VOTE: <u>Review and Approval of January 16, 2019 P&T Minutes</u> Approved recommendations as presented. <u>Motion:</u> Ronald Ruggiero, Pharm. D <u>2nd</u> Maria Lopez, Pharm. D <u>Vote:</u> <i>Unanimous approval (9/9)</i> <i>(Other members arrived afterwards)</i></p>
<p>****Adjourn to Closed Session**** Closed Session pursuant to Welfare and Institutions Code Section 14087.36 (w)</p>				
5.	<p>Discussion and Recommendation for Change to SFHP Formulary and Prior Authorization Criteria for Select Drug Classes.</p>	Kaitlin Hawkins, Pharm. D	<p><i>The following drug classes were reviewed for pertinent literature (including meta-analyses and pivotal clinical trials), guideline updates, and drug additions to or removals from market since last class review.</i></p>	<p>VOTE: <u>Formulary Maintenance Items:</u> Approved recommendations as presented.</p>

	Topic	Brought By	Discussion	Action
	<p>Formulary Maintenance Items: <u>Endocrinology:</u> Enzyme Therapy (pp.14 - 27 of April 2019 P&T Packet)</p>		<p>Major recommendations included the following: Last reviewed: April 2017 Formulary Update: (Medi-Cal, Healthy Kids HMO, and Healthy Workers HMO) • None Prior Authorization Criteria Update: • None Drug Utilization Review Update: • None Committee Discussion: <i>The committee had no comments or questions.</i></p>	<p><u>Motion:</u> Ted Li, MD 2nd: Joseph Pace, MD <u>Vote:</u> Unanimous approval (11/11)</p>
6.	<p>Formulary Maintenance Items: <u>Endocrinology:</u> Antidiuretic Hormone (pp.14 - 27 of April 2019 P&T Packet)</p>		<p>Last reviewed: April 2017 Formulary Update: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco) • None Prior Authorization Criteria Update: • Remove parenteral desmopressin listing from criteria due to lack of utilization and availability through the medical benefit Drug Utilization Review Update: • None Committee Discussion: <i>The committee had no comments or questions.</i></p>	
7.	<p>Formulary Maintenance Items: <u>Dermatology:</u> Atopic Dermatitis (pp.14 - 27 of April 2019 P&T Packet)</p>		<p>Last reviewed: July/October 2017 Formulary Update: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco) • Add Dupixent® (dupilumab) to formulary tier 4 with PA required and restricted to specialty network Prior Authorization Criteria Update: • Update Atopic Dermatitis criteria to remove requirement of prior trial with Eucrisa® (crisaborole) for Dupixent® use, and include newly approved age group for Dupixent® Drug Utilization Review Update: • None Committee Discussion: <i>The committee had no comments or questions.</i></p>	
8.	<p>Formulary Maintenance Items: <u>Dermatology:</u> Psoriasis (traditional therapies) (pp.14 - 27 of April 2019 P&T Packet)</p>		<p>Last reviewed: July 2017 Formulary Update: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco) • Remove step requirement for calcipotriene (Dovonex®) 0.005% cream and ointment and maintained on formulary tier 1 with quantity limit #60 per 30 days • Remove calcitriol (Vectical®) 3mcg/g ointment from formulary due to lack of utilization and cost-effective</p>	

	Topic	Brought By	Discussion	Action
			<p>alternatives available</p> <p>Prior Authorization Criteria Update:</p> <ul style="list-style-type: none"> Retire Topical Vitamin D Analogs criteria <p>Drug Utilization Review Update:</p> <ul style="list-style-type: none"> None <p>Committee Discussion: <i>The committee had no comments or questions.</i></p>	
9.	<p>Formulary Maintenance Items: Cardiology: Dyslipidemia (pp.14 - 27 of April 2019 P&T Packet)</p>		<p>Last reviewed: January 2018 (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco)</p> <ul style="list-style-type: none"> None <p>Prior Authorization Criteria Update:</p> <ul style="list-style-type: none"> None <p>Drug Utilization Review Update:</p> <ul style="list-style-type: none"> None <p>Committee Discussion: <i>The committee had no comments or questions.</i></p>	
10.	<p>Neurology: Lokelma (Na zirconium cyclosilicate) Monograph (pp.28 - 34 of April 2019 P&T Packet)</p>	Kaitlin Hawkins, Pharm. D	<p><i>The plan presented a monograph and recommendations for Neurology medications.</i> <i>Major recommendations included the following:</i></p> <p>Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco)</p> <ul style="list-style-type: none"> Add Lokelma™ to formulary tier 2 with quantity limit #35 per 30 days Remove Veltassa® from formulary and grandfather any current users <p>Prior Authorization Criteria (PA) Recommendations:</p> <ul style="list-style-type: none"> None (no active criteria) <p>Drug Utilization Review (DUR) Recommendations:</p> <ul style="list-style-type: none"> None <p>Committee Discussion: <i>The committee had no comments or questions.</i></p>	<p>VOTE: Neurology: Approved recommendations as presented.</p> <p><u>Lokelma (Na zirconium cyclosilicate) Monograph</u></p> <p><i>Motion:</i> Robert (Brad) Williams, MD 2nd: Joseph Pace, MD <i>Vote:</i> Unanimous approval (11/11)</p>
11.	<p>Rheumatology Biologic and Non-Biologic DMARDs Class Review (pp.35 - 67 of April 2019 P&T Packet)</p>	Kent Truong, Pharm. D	<p><i>The plan presented a class review and recommendations for Rheumatology medications.</i> <i>Major recommendations included the following:</i></p> <p>Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco)</p> <ul style="list-style-type: none"> Add Olumiant® to formulary tier 4 specialty with prior authorization required to ensure appropriate diagnosis, and prefer over Xeljanz® for rheumatoid arthritis based on relative cost-effectiveness and emerging safety data Add Orencia®, Kineret®, Otezla®, Cimzia®, Simponi®, Cosentyx®, and Stelara® to Healthy Workers HMO formulary tier 3 with prior authorization required to align with Medi-Cal and Healthy Kids HMO 	<p>VOTE: Rheumatology Approved recommendations as presented.</p> <p><u>Biologic and Non-Biologic DMARDs Class Review</u> <i>Motion:</i> Ronald Ruggiero, Pharm. D 2nd: Nicholas Jew, MD <i>Vote:</i> Unanimous approval (11/11)</p>

	Topic	Brought By	Discussion	Action
			<p>(specialty is not utilized for HW)</p> <p>PA Criteria Recommendations:</p> <ul style="list-style-type: none"> • Update Disease Modifying Biologics to include limumya® as non-formulary • Update Disease Modifying Biologics to include the following as non-preferred agents due to their expanded FDA-approved indications <ul style="list-style-type: none"> ○ Polyarticular and Systemic Juvenile Idiopathic Arthritis: Actemra® ○ Psoriatic Arthritis: Taltz® and Xeljanz® ○ Plaque Psoriasis: Cimzia® ○ Ulcerative Colitis: Xeljanz® • For the diagnosis of plaque psoriasis and psoriatic arthritis, moved Cosentyx® and Taltz® to parity with Humira® and Enbrel® due long-term safety and efficacy data and superior efficacy compared to older biologic agents • For the diagnosis of plaque psoriasis, require light therapy unless contraindicated prior to biologic therapy • For the diagnosis of ankylosing spondylitis, move Cosentyx® to parity with Humira® and Enbrel® due to long-term safety and efficacy data • Add criteria and dosing for Humira in hidradenitis suppurativa based on FDA indication <p>DUR Recommendations:</p> <ul style="list-style-type: none"> • None <p>Committee Discussion:</p> <p><i>The committee had no comments or questions.</i></p>	

	Topic	Brought By	Discussion	Action
12.	Endocrinology Osteoporosis Class Review (pp.68 - 81 of April 2019 P&T Packet)	Kaitlin Hawkins, Pharm. D	<i>The plan presented class reviews and recommendations for Endocrinology medications.</i> <i>Major recommendations included the following:</i> Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco) <ul style="list-style-type: none"> Add Tymlos® to formulary and require prior authorization to ensure appropriate diagnosis Remove Prolia® and Xgeva® injections from formulary as they require administration by a healthcare professional and should be provided via the medical benefit Prior Authorization Criteria Recommendations: <ul style="list-style-type: none"> Update Forteo® (teriparatide) criteria to include Tymlos® and prefer over Forteo® for postmenopausal osteoporosis Update Bisphosphonates criteria to reflect current ibandronate formulary status Retire Prolia® and Xgeva® (denosumab) criteria based on restriction to medical benefit DUR Recommendations: <ul style="list-style-type: none"> None Committee Discussion: <i>The committee had no comments or questions.</i>	VOTE: Endocrinology Approved recommendations as presented. <u>Osteoporosis Class Review</u> <i>Motion:</i> Ronald Ruggiero, Pharm. D <i>2nd:</i> Linda Truong, Pharm. D <i>Vote:</i> <i>Unanimous approval (11/11)</i>
13.	Endocrinology Systemic Corticosteroids Abbreviated Class Review (pp.82 – 88 of April 2019 P&T Packet)	Jenna Heath , Pharm. D	Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco): <ul style="list-style-type: none"> None PA Criteria Recommendations: <ul style="list-style-type: none"> None DUR Recommendations: <ul style="list-style-type: none"> None Committee Discussion: <i>The committee had no comments or questions.</i>	VOTE: Endocrinology Approve recommendations as presented. <u>Systemic Corticosteroids Abbreviated Review</u> <i>Motion:</i> Lisa Ghotbi, Pharm. D <i>2nd:</i> Ted Li, MD <i>Vote:</i> <i>Unanimous approval (11/11)</i>
14.	Pulmonology Asthma/COPD Class Review (pp. 89 - 115 of April 2019 P&T Packet)	Jenna Heath, Pharm. D	<i>The plan presented a class review and recommendations for Pulmonology medications.</i> <i>Major recommendations included the following:</i> Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO and Healthy San Francisco): <ul style="list-style-type: none"> Remove Spiriva Handihaler® from formulary and prefer Spiriva Respimat® (grandfather current users) PA Criteria Recommendations: <ul style="list-style-type: none"> Update Inhaled Beta-Adrenergic and Glucocorticoid Combinations (ICS/LABA) PA criteria based on available generic inhalers DUR Recommendations: <ul style="list-style-type: none"> Consider developing provider education to optimize 	VOTE: Pulmonology Approve recommendations as presented. <u>Asthma/COPD Class Review</u> <i>Motion:</i> Joseph Pace, MD <i>2nd:</i> Maria Lopez, Pharm. D <i>Vote:</i> <i>Unanimous approval (11/11)</i>

	Topic	Brought By	Discussion	Action
			<p>use of generic ICS/LABA inhalers where appropriate</p> <ul style="list-style-type: none"> Evaluate member adherence with controller therapy versus rescue therapy use for potential further education <p>Committee Discussion: <i>The committee had no comments or questions.</i></p>	
15.	<p><u>Pulmonology</u> Pulmonary Biologics Class Review (pp.116 - 128 of April 2019 P&T Packet)</p>	Jenna Heath, Pharm. D	<p>Formulary Recommendations: <u>(Medi-Cal, Healthy Kids HMO, Healthy Workers HMO and Healthy San Francisco):</u></p> <ul style="list-style-type: none"> Add Dupixent® to formulary tier 4 with prior authorization required to ensure appropriate diagnosis and use of preferred therapies as appropriate Remove Xolair® from formulary and remove prior authorization due to preferred alternatives and required administration by a healthcare professional <p>PA Criteria Recommendations:</p> <ul style="list-style-type: none"> New criteria is proposed for Dupixent® in asthma Update atopic dermatitis criteria to include “For requests for Dupixent for asthma diagnosis, refer to Pulmonary Biologics criteria” <p>DUR Recommendations:</p> <ul style="list-style-type: none"> None <p>Committee Discussion: <i>The committee had no comments or questions.</i></p>	<p>VOTE: <u>Pulmonology</u> Approve recommendations as presented.</p> <p><u>Pulmonary Biologics Class Review</u> <i>Motion: Robert (Brad) Williams, MD</i> <i>2nd: Nicholas Jew, MD</i> <i>Vote: Unanimous approval (11/11)</i></p>
16.	<p><u>Neurology</u> Tegsedi (inotersen) Monograph (pp.129 - 132 of April 2019 P&T Packet)</p>	Jenna Heath, Pharm. D	<p><i>The plan presented a monograph and recommendations for Neurology medications.</i> <i>Major recommendations included the following:</i></p> <p>Formulary Recommendations: <u>(Medi-Cal, Healthy Kids HMO, Healthy Workers HMO and Healthy San Francisco):</u></p> <ul style="list-style-type: none"> None <p>PA Criteria Recommendations:</p> <ul style="list-style-type: none"> None (no active criteria) <p>DUR Recommendations:</p> <ul style="list-style-type: none"> None <p>Committee Discussion: <i>The committee had no comments or questions.</i></p>	<p>VOTE: <u>Neurology</u> Approve recommendations as presented.</p> <p><u>Tegsedi (inotersen) Monograph</u> <i>Motion: Ronald Ruggiero, Pharm. D</i> <i>2nd: Linda Truong, Pharm. D</i> <i>Vote: Unanimous approval (11/11)</i></p>
17.	<p><u>Immunology</u> Immunosuppressants Class Review (pp.133 -142 of April 2019 P&T Packet)</p>	Kaitlin Hawkins, Pharm. D	<p><i>The plan presented a class review and recommendations for Immunology medications. Major recommendations are listed below.</i></p> <p>Formulary Recommendations: <u>(Medi-Cal, Healthy Kids HMO, Healthy Workers HMO and Healthy San Francisco):</u></p> <ul style="list-style-type: none"> Add the following drugs to formulary based on utilization and high approval rates: <ul style="list-style-type: none"> Zortress® oral tablets (all strengths) to tier 2 sirolimus oral tablets (all strengths) to tier 1 	<p>VOTE: <u>Immunology</u> Approve recommendations as presented.</p> <p><u>Immunosuppressants Class Review</u> <i>Motion: Maria Lopez, Pharm. D</i> <i>2nd: Jaime Ruiz, MD</i> <i>Vote: Unanimous approval (11/11)</i></p>

	Topic	Brought By	Discussion	Action
			<ul style="list-style-type: none"> Add the following drugs to formulary with age limit based on limited alternatives and high approval limits: <ul style="list-style-type: none"> Rapamune® 1mg/mL oral solution to tier 2 cyclosporine modified 100mg/mL oral solution to tier 1 Move cyclosporine 25, 100 mg capsules from formulary with prior authorization to non-formulary (T5-NF) due to lack of utilization and available alternatives <p>PA Criteria Recommendations:</p> <ul style="list-style-type: none"> Retire Immunosuppressants criteria based on formulary changes above; use blanket criteria for requests outside recommended age limits or for non-formulary drugs <p>DUR Recommendations:</p> <ul style="list-style-type: none"> None <p>Committee Discussion: <i>The committee had no comments or questions.</i></p>	
18.	<p>Obstetrics & Gynecology Endometriosis Class Review (pp.143 - 153 of April 2019 P&T Packet)</p>	Kaitlin Hawkins, Pharm. D	<p><i>The plan presented a class review and recommendations for Immunology medications. Major recommendations are listed below.</i></p> <p>Formulary Recommendations: <i>(Medi-Cal, Healthy Kids HMO, Healthy Workers HMO and Healthy San Francisco):</i></p> <ul style="list-style-type: none"> Add Orilissa™ (elagolix) oral tablet to formulary (tier 3) due to limited alternatives available, with prior authorization required to ensure appropriate diagnosis Add Lupron® Depot 3.75 (1-mo) and 11.25mg (3-mos) kits to Healthy Workers HMO formulary tier 3 prior authorization with required to ensure appropriate diagnosis, to align with other lines of business Remove Synarel® nasal spray from formulary due to lack of utilization or requests and cost-effective alternatives available <p>PA Criteria Recommendations:</p> <ul style="list-style-type: none"> Update Gonadotropin Releasing Hormone (GnRH) Agonists—Obstetric criteria to include Orilissa™ <p>DUR Recommendations:</p> <ul style="list-style-type: none"> None <p>Committee Discussion: <i>The committee had no comments or questions.</i></p>	<p>VOTE: Obstetrics & Gynecology Approve recommendations as presented.</p> <p>Endometriosis Class Review <i>Motion: Maria Lopez, Pharm. D</i> <i>2nd: Jaime Ruiz, MD</i> <i>Vote: Unanimous approval (11/11)</i></p>
19.	<p>Drug Utilization Review (DUR)</p> <ul style="list-style-type: none"> DUR Program Updates Prospective Program Reports <p>(pp.1154 - 175 of April 2019 P&T Packet)</p>	Jessica Shost, Pharm. D Kaitlin Hawkins, Pharm. D	<p><i>DUR Program Updates</i> <i>Prospective Program Reports:</i></p> <ul style="list-style-type: none"> <i>Prospective DUR quarterly report Q3.2018</i> <i>Prospective DUR quarterly report Q4.2018</i> <p>Committee Discussion: <i>The committee requested the Specialty cost to be added to the Pharmacy Trend Report.</i></p>	Non-Voting Items

****RECONVENE IN OPEN SESSION****

	Topic	Brought By	Discussion	Action
20.	Summary of Closed Session	James Glauber, MD	Reconvened Open session around 9:05 am	<i>Non-voting item</i>
21.	Review and Approval of Prior Authorization Criteria Interim Changes (pp.176 – 179 April 2019 P&T Packet)	Kaitlin Hawkins, Pharm. D	<i>The plan presented Prior Authorization interim changes of (New Criteria, Revised Existing Criteria & a table of criteria that were evaluated per the Annual review process where no clinical changes were mad) for review and approval that will be implemented on 2/20/2019:</i> <u>Committee Discussion:</u> <i>The committee had no comments or questions.</i>	VOTE: <u>Review and Approval of Prior Authorization Criteria Interim Changes</u> Approve recommendations as presented. <i>Motion:</i> Ronald Ruggiero, Pharm. D <i>2nd:</i> Jaime Ruiz, MD <i>Vote:</i> Unanimous approval (11/11)
22.	Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market (pp.180 – 193 of April 2019 P&T Packet)	Kaitlin Hawkins, Pharm. D	<i>The plan presented interim formulary changes and formulary status for new drugs to market.</i> <u>Committee Discussion:</u> <i>The committee had no comments or questions.</i>	VOTE: <u>Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market</u> Approve recommendations as presented. <i>Motion:</i> Ronald Ruggiero, Pharm. D <i>2nd:</i> Jaime Ruiz, MD <i>Vote:</i> Unanimous approval (11/11)
23.	Informational Update on New Developments in the Pharmacy Market (pp.194 – 200 of April 2019 P&T Packet)	Jenna Heath, Pharm. D	<i>The plan provided information on new developments in the pharmacy market.</i>	<i>Non-voting item</i>
24.	Adjournment	James Glauber, MD	The meeting adjourned at 9:25 am. 2019 – 2020 P&T Committee Meeting dates are: <ul style="list-style-type: none"> • Wednesday, July 17, 2019 • Wednesday, October 16, 2019 • Wednesday, January 15, 2020 • Wednesday, April 15, 2020 	

Respectfully submitted by:

James Glauber, MD, MPH
Chief Medical Officer

April 30, 2019

Date